The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | HRQoL in KEYNOTE-966: pembrolizumab with gemcitabine and cisplatin for advanced biliary tract cancer
In the Phase 3 KEYNOTE-966 trial (NCT04003636), the addition of pembrolizumab to gemcitabine/cisplatin as first-line therapy for unresectable locally advanced or metastatic biliary tract cancer (BTC) significantly improved overall survival (OS) with a manageable safety profile. In this update, Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Korea, discusses exploratory patient-reported outcomes (PROs) from KEYNOTE-966. PROs were assessed using various questionnaires, and the analysis showed that health-related quality of life (HRQoL) was maintained with pembrolizumab + gemcitabine/cisplatin treatment. These PRO results, along with the efficacy and safety data, support pembrolizumab + gemcitabine/cisplatin as a new first-line treatment option for advanced BTC. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
